News Archive

September 2015

• Press Release Sep 24, 2015

  Novartis appoints James E. Bradner, MD as President of the Novartis Institutes for BioMedical Research as Mark Fishman retires

  New leader to continue to drive long-term innovation in Novartis research in wide range of therapeutic areas Basel, September 24, 2015 - Novartis announced today that Dr. James (Jay) E.…
• Press Release Sep 24, 2015

  Novartis nomme le Dr James E. Bradner Président des Instituts Novartis pour la Recherche Biomédicale suite au prochain départ à la retraite de Mark Fishman

  Un nouveau responsable pour continuer de stimuler l'innovation à long terme au sein de la recherche chez Novartis dans des domaines thérapeutiques très variés Bâle, le 24 septembre 2015 -…
• Press Release Sep 24, 2015

  Novartis ernennt Dr. James E. Bradner zum Präsidenten der Novartis Institutes for BioMedical Research, da Mark Fishman in den Ruhestand tritt

  Neuer Leiter wird weiterhin langfristige Innovationen in zahlreichen Therapiegebieten der Novartis Forschung vorantreiben Basel, 24. September 2015 - Novartis gab heute bekannt, dass…
• Press Release Sep 24, 2015

  Novartis launches 'Novartis Access', a portfolio of affordable medicines to treat chronic diseases in lower-income countries

  First-of-its-kind portfolio approach in healthcare industry, aiming to increase availability and affordability of 15 medicines against cardiovascular diseases, diabetes, respiratory illnesses and…
• Press Release Sep 24, 2015

  Novartis lance « Novartis Access », une gamme de médicaments à prix abordables pour lutter contre les maladies chroniques dans les pays à faible revenu

  Une approche unique en son genre dans l'industrie de la santé, qui vise à rendre 15 médicaments plus facilement disponibles et plus accessibles pour traiter les maladies cardiovasculaires, le diabète…
• Press Release Sep 24, 2015

  Novartis lanciert "Novartis Access", ein Portfolio von erschwinglichen Medikamenten zur Behandlung von chronischen Erkrankungen in Ländern mit niedrigen Einkommen

  Neuartiger Portfolioansatz in der Gesundheitsbranche mit dem Ziel, die Verfügbarkeit und Erschwinglichkeit von 15 Medikamenten gegen Herz-Kreislauf-Erkrankungen, Diabetes, Atemwegserkrankungen und…
• Press Release Sep 18, 2015

  Swissmedic approves Novartis' new heart failure medicine Entresto(TM)

  Decision by Swiss Health Authority follows US Food and Drug Administration (FDA) approval of Entresto in July, serves as an important reference approval for multiple other health authorities…
• Press Release Sep 07, 2015

  Novartis Foundation healthcare models and disease elimination programs showcased at ECTMIH

  Telemedicine pilot in rural Ghana demonstrated positive impact and improved primary health services as reported by nurses, midwives and patients  Retrospective contact tracing of former leprosy…
• Press Release Sep 04, 2015

  Novartis receives EU approval for Farydak®, the first in its class of anticancer agents approved for patients with multiple myeloma

  Farydak (panobinostat) combination is approved in the EU for patients with multiple myeloma who received >=2 prior regimens including bortezomib and IMiD[1] In clinical trials, Farydak…
• Press Release Sep 03, 2015

  Sandoz launches ZarxioTM (filgrastim-sndz), the first biosimilar in the United States

  Launch follows March 6, 2015 FDA approval Sandoz One SourceTM offers patient support services The digital press release with multimedia content can be accessed here:   Holzkirchen,…
• Press Release Sep 02, 2015

  Novartis receives EU approval for new Revolade® use as first-in-class therapy for patients with severe aplastic anemia

  Revolade is the first approved therapy in the EU for patients with severe aplastic anemia (SAA) who have not responded to other treatments  Patients living with SAA, a rare blood disorder,…
• Press Release Sep 01, 2015

  Novartis announces global partnership with Amgen to develop and commercialize pioneering neuroscience treatments

  The companies plan to co-develop and co-commercialize a BACE inhibitor program in Alzheimer's Disease (AD); Novartis' oral therapy CNP520 will be the lead molecule  Novartis and Amgen also plan…